Elsevier has created a Monkeypox Information Center in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
Short communication

The virology of human monkeypox virus (hMPXV): A brief overview

Edouard Lansiaux a,1,*, Nityanand Jain b,1,*, Sniedze Laivacuma c, Aigars Reinis d

a Lille University School of Medicine, 2 Avenue Eugène Avinée, 59120, Lille, France
b Faculty of Medicine, Riga Stradins University, Dzirciema Street 16, Riga LV-1007, Latvia
c Department of Infectionology, Riga Stradins University, Dzirciema Street 16, Riga LV-1007, Latvia
d Department of Biology and Microbiology, Riga Stradins University, Dzirciema Street 16, Riga LV-1007, Latvia

ARTICLE INFO

Keywords:
Monkeypox virus
Global
Sexual transmission
Virology
Pandemic
Infections
hMPXV

ABSTRACT

First described in 1958, the human monkeypox virus (hMPXV) is a neglected zoonotic pathogen closely associated with the smallpox virus. The virus usually spreads via close contact with the infected animal or human and has been endemic mostly in parts of the African continent. However, with the recent increase in trade, tourism, and travel, the virus has caused outbreaks in countries outside Africa. The recent outbreak in 2022 has been puzzling given the lack of epidemiological connection and the possible sexual transmission of the virus. Furthermore, there is limited understanding of the structural and pathogenetic mechanisms that are employed by the virus to invade the host cells. Henceforth, it is critical to understand the working apparatus governing the viral-immune interactions to develop effective therapeutical and prophylactic modalities. Hence, in the present short communication, we summarize the previously reported research findings regarding the virology of the human monkeypox virus.

On the 7th of May 2022, the UKHSA (United Kingdom Health Security Agency) confirmed the first case of the human Monkeypox Virus (hMPXV) in a case travelling back from Nigeria. The patient had developed rashes a few days ago before travelling to the UK but presented to the hospital on the day of his arrival in the UK. A reverse transcriptase polymerase chain reaction (RT-PCR) on a vesicular swab was performed and the hMPXV infection was confirmed (World Health Organization (WHO), 2022). Since then, more than 1500 cases in 45 countries have been suspected and/or confirmed (as of 11th June 2022) (Van Ranst, 2018). Hence in the present paper, we summarize the latest advances that have been reported regarding the virology of hMPXV.

1. Origins of the virus

The virus was first isolated in 1958 from smallpox-like vesiculopustular lesions amongst the captive imported monkeys (Java macaques) at the State Serum Institute in Copenhagen, Denmark (von Magnus, Andersen and Petersen, 1959). The monkeys were reported to suffer from a spontaneous outbreak of fever and rash. Over the next few years, similar outbreaks were reported in monkeys elsewhere. In 1966, the virus was identified as the causative agent behind a widespread classical apoptotic mimicry mechanism for entry into the host cells (Swiss Institute of Bioinformatics (SIB), 2022; Amara and Mercer, 2015).

Recent bibliometric analyses have shed light on the limited literature that is available on the pathogenesis, origins, and treatment of hMPXV (Cheng et al., 2022; Rodríguez-Morales et al., 2022). This is extremely concerning since the virus is characterized as Biosafety Level 3 (high threat) pathogen in the EU and is on the list of select agents in the United States (Central African clade) (Tian and Zheng, 2014; Sklenovská and Van Ranst, 2018). Hence in the present paper, we summarize the latest advances that have been reported regarding the virology of hMPXV.

Abbreviations: MPXV, monkeypox virus; WHO, World Health Organization; CA Clade, Central African Clade; WA Clade, West African Clade.

* Corresponding author.
E-mail addresses: edouard.lansiaux.etu@univ-lille.fr (E. Lansiaux), nityaykl@gmail.com (N. Jain), sniedze.laivacuma@rsu.lv (S. Laivacuma), aigars.reinis@rsu.lv (A. Reinis).
1 Both authors contributed equally (co-first authors).

https://doi.org/10.1016/j.virusres.2022.198932
Received 10 July 2022; Received in revised form 17 September 2022; Accepted 18 September 2022
Available online 19 September 2022
0168-1702/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
outbreak at a zoo in Rotterdam (Dumbell and Smith, 1999). The virus was believed to have first affected the South American giant anteaters before spreading to various species of apes and monkeys. It was in 1970 that two separate incidents of smallpox-like disease in individuals from the Democratic Republic of Congo and Liberia were reported that led to the recognition of hMPXV as a distinct virus (Dumbell and Smith, 1999).

From 1970 to 2003, the virus was endemic to the rainforests of central and western African countries. In 2003, the first report of an outbreak outside Africa was reported in the US, when a shipment of exotic animals including nine different species of mammals was imported from Ghana (Ligon, 2004). The imported mammals were transported to different states with other animals, causing widespread infection of animals. Only after a 3-year-old girl was brought to the emergency after being bitten by a prairie dog, source tracing indicated a spill-over event (Ligon, 2004). Since then, sporadic outbreaks have been noted across the globe, all having traceable origins in the endemic African regions.

Given its capability to infect multiple mammalian taxa, its natural reservoir is still under investigation. Although monkeys have been eliminated as candidates for being the natural reservoir for the virus (Moss, 2020), rope squirrels and sooty mangabey are considered potential natural viral reservoirs (Khodakevich et al., 1986; Radonić et al., 2014).

2. MPXV clades – similarities & differences

The Orthopoxvirus are antigenically and genetically similar (Fig. 2), with open reading frames (ORFs) having >90% sequence identity amongst its members (Shchelkunov et al., 2002). These viruses are undergoing evolutionary changes that are driven by progressive gene loss primarily at the terminal ends of the genome (Hendrickson et al., 2010; Kugelman et al., 2014). These changes could be accelerated by selective pressure from a host species (Hendrickson et al., 2010; Kugelman et al., 2014). Variations in gene copy number is another theory explaining the increasing viral fitness towards human infection and transmission (Elde et al., 2012). The 197 kb linear DNA genome of hMPXV contains close to 190 non-overlapping ORFs each longer than 60 amino acid residues (Hendrickson et al., 2010; Shchelkunov et al., 2001). The highly conserved central coding region sequence (CRS) is located at nucleotide positions 56,000–120,000 and is flanked by variable ends containing the inverted terminal repeats (ITRs) (Kugelman et al., 2014; Moss, 2001). There are at least four known ORFs in the ITR region of the hMPXV genome.

Fig. 1. Cluster network charts showing the spread of the human Monkeypox Virus (hMPXV) as of 25th May 2022. (A) Clustering based on country and contact tracing; (B) Clustering based on date of case confirmation and contact tracing.
The hMPXV has two described clades – the Central African/Congo Basin (CA) and West African (WA) clades. Similar to SARS-COV-2 (Covid-19), calls have been raised to rename the two clades to Clade 1 (CA) and Clades 2 and 3 (WA), in line with best international practices to move away from stigmatizing and discriminating nomenclature typically associated with geographic regions, nations, economies, and people (Happi et al., 2022). Accordingly, it has been recommended to assign hMPXV.B.1 to the lineage behind the current outbreak in Europe and the Global North (Happi et al., 2022).

The CA clade has estimated case mortality of 10% in non-vaccinated individuals with known human-human transmission whilst the WA clade has been associated with a milder form of the disease with lower mortality and less evident human-human transmission (Bunge et al., 2022). Genomic comparative studies have revealed a 0.55–0.56% nucleotide difference between the two clades (Chen et al., 2005), with the CA clade possessing 173 functional unique genes compared to 171 of the WA clade. The two clades were found to be 99.4% identical, sharing 170 orthologs at the protein level with no significant differences in the transcriptional regulatory sequences (Chen et al., 2005; Weaver and Isaacs, 2008). Amongst the virulence genes, 53 out of 56 were found in both clades and showcased 61 conservative, 93 non-conservative, and 121 silent amino acid changes (Chen et al., 2005).

The differences in virulence between the two clades have been postulated to stem from the differences in the gene orthologs - BR-203 (virulence protein), BR-209 (II-1β binding protein), and COP-C3L (inhibitor of complement enzymes) (Chen et al., 2005; Likos et al., 2005).

Other candidate gene orthologs include the WA clade-specific COP-A49R (unknown function) and COP-A52R (Bifunctional Toll-IL-1-receptor protein). In terms of CA clade-specific orthologs, candidates include BR-19 and BR-20 (unknown function) (Weaver and Isaacs, 2008). Another crucial gene responsible for the difference in virulence in clades is the D14R gene-coded inhibitor of complement-binding protein (MOPICE), an important anti-inflammatory factor that is absent from the hMPXV WA clade (Chen et al., 2005; Lopera et al., 2015; Liszewski et al., 2006). However, these genes are not the only factors responsible for virulence, with many more candidates yet to be identified.

Recently, four genomes of the hMPXV isolated during the 2022 outbreak (Germany, USA, Portugal, and Belgium) were published online by various groups of researchers (Isidro et al., 2022; Gigante et al., 2022; Antwerpen et al., 2022; Selhorst et al., 2022). A compiled version of the genomes for visualization is available at https://nextclade.org/monkeypox (Accessed 29th May 2022). Analysis of the genomes preliminarily hints at a very strong bias in mutations of bases Guanine (G) to Adenine (A) and Cytosine (C) to Thymine (T). The enzyme APOBEC3 (Apolipoprotein B Editing Complex), a cytidine deaminase, has been postulated to be responsible for these mutations (Rambaut, 2022). A genomic comparison from viral isolates from 2015 to 2022 showed a 30-T base long sequence in the middle of the viral genome, the role of which is yet to be determined (Perez and Lounnas, 2022).
3. Viral pathogenesis

The pathogenesis of the hMPXV involves viral entry, fusion, replication, and release, during which the virus produces two infectious forms - extracellular enveloped virions (EV) and intracellular mature virions (MV). Whilst MVs are single membrane-bound that are released only during host cell lysis, EVs are specialized MVs that are bound by an antigendically distinct triple membrane (the double membrane is gained by translocation to Golgi bodies) (Reallegeno et al., 2020; Mucker et al., 2022a). It has been demonstrated that vaccines and antibodies that fail to produce or target the EV antigens provide lower protection than those including both (Golden et al., 2011; Lustig et al., 2005).

In the context of Orthopoxviruses, two multi-subunit complexes are crucial for completing the viral infectious cycle – GARP (Golgi-Associated Retrograde Protein) and COG (Conserved Oligomeric Golgi) complex (Reallegeno et al., 2020). The GARP complex, responsible for retrograde endosomal transport, comprises four vacuolar protein sorting (VPS) genes – VPS51, VPS52, VPS53, and VPS54, all of which were found to be enriched in both CA and WA clades (except VPS53 which is specifically enriched in CA clade) (Reallegeno et al., 2017). VPS52 and VPS54 knockout cells infected with MPXV have shown a significant decrease in EV yield, thereby confirming their prominent function in virus egress and cell-to-cell spread (Reallegeno et al., 2017).

The COG complex, required for maintaining Golgi structure and intra-Golgi traffic regulation, comprises two lobes, each with four associated subunits (Lobe A – COG1, COG2, COG3, COG4, and Lobe B – COG5, COG6, COG7, COG8) (Reallegeno et al., 2020). COG7 and COG8 are enriched in both clades whilst COG3 and COG4 are enriched only in the CA clade (Reallegeno et al., 2017). COG4 and COG7 are thought to be the most important subunits for viral fusion (Reallegeno et al., 2020).

Bioinformatic analysis of the hMPXV CA genome revealed two distinct regions (R1 – Open Reading Frame 17 to 32 and R2 – Open Reading Frame 179 to 193), deletion of which could attenuate the virulence of hMPXV (Lopera et al., 2015). Deletion of either or both regions led to reduced mice mortality and morbidity whilst attenuating viral replication (Lopera et al., 2015). The authors further were able to attribute genes in region R1 to be responsible for viral replication whilst those in region R2 to be responsible for viral pathogenicity (Lopera et al., 2015). A dual deletion of R1 and R2 was the most effective in suppressing viral virulence (Lopera et al., 2015).

Microarray analysis has revealed that hMPXV induces histone post-translational modification in the host cell by the downregulation of histone expression regulation factors and upregulation of core histones (Alkhali et al., 2010). These changes could indicate the dependence of viral DNA compaction and nucleosome formation on the expression of host cell histones (Alkhali et al., 2010). Additionally, the authors reported a downregulation in the expression of cell membrane ion channels coupled with gene regulation favouring G2 phase cell arrest and S phase progression (Alkhali et al., 2010).

4. Cytokine storm

Similar to the cytokine storm that is induced by Covid-19 infection (Ragab et al., 2020), a study performed cytokine profiling on 19 patients with PCR-confirmed hMPXV infection and reported on the correlation between the degree of cytokine modulation and the severity of hMPXV infection in patients (Johnston et al., 2015). The cytokine storm seemed to be Th2 mediated with interleukins IL-4, 5, 6, and 10 (IL-10 is a strong marker for cytokine storm) being significantly above the normal levels with an associated depression of Th1 associated cytokines II-2, -12, TNF-α (tumor necrosis factor-alpha), and IFN-α and -γ (interferon alpha and gamma) (Johnston et al., 2015).

It has been demonstrated that Orthopoxvirus infection including hMPXV induces a cascade of complementary B cell responses that encodes for multiple cross-species reactive antigen clones (Gilchuk et al., 2016). The six crucial identified monoclonal antibodies (mAbs) were targeted against H3, A27, D8, and L1 (MV antigens) and B5 and A33 (EV antigens). A cocktail of A33, B5, L1, and A27 was demonstrated to be the primary provider of protection against orthopoxviral respiratory tract infection whilst a cocktail of all six mAbs was responsible for protection against systemic infection (Gilchuk et al., 2016). Such cocktails were also found to be more therapeutically effective than VIGIV (Vaccinia Immune Globulin Intravenous) (Gilchuk et al., 2016).

5. Advances in diagnostic modalities for hMPXV

The major diagnostic modalities for hMPXV include PCR, viral culture and isolation, negative staining electron microscopy of the rash, immunohistochemistry for orthopoxviral specific antigens, and IgM/IgG serology testing (Brown and Leggat, 2016). A rapid lateral flow-based screening test called Tetracore Orthopox BioThreat Alert® is available to prioritize sample testing for hMPXV (Brown and Leggat, 2016). An even more sensitive point-of-care diagnostic tool based on gravity-driven flow-through antigen capture ELISA has been also developed (Stern et al., 2016). Known as the ABICAP (Antibody Immuno Column for Analytical Processes) immunofiltration tool, it can detect all zoonotic orthopoxviruses. Recently, a rapid under seven minutes recombinase polymerase amplification (RPA) assay was developed which targets the G2R gene of the virus (Davi et al., 2019). The assay demonstrated 100% specificity with 95% sensitivity in detecting both clades of the virus.

Serological and protein-based diagnostic tests suffer from the limitation of cross-reactivity between different Orthopoxvirus species. To overcome this limitation, research groups have tried to identify highly specific antibodies that could be used for screening and diagnostic testing. One such identified antibody is 69–126–3–7 which binds to the A27 protein of the hMPXV (Hughes et al., 2014). Other potential antibodies have been described by Keasey et al. (2010) Animal studies have shown that evaluation of lymph node size and metabolic activity is a reliable predictor of hMPXV disease severity and course. Positron emission tomography/computed tomography imaging with [18F]-fluorodeoxyglucose (FDG) has been demonstrated to predict the course of hMPXV disease in non-human primate models (Dyall et al., 2017). Increased FDG uptake with minimal lymph node enlargement in the early stages of the disease was found to be negatively associated with survival (Dyall et al., 2017).

6. Advances and challenges in treatment and prophylaxis

It has been demonstrated that 24 hours after exposure to lethal hMPXV in monkeys, initiation of antiviral treatment with cidofovir or with a related acyclic nucleoside phosphonate analogue is more effective than smallpox vaccination (Stittelaar et al., 2006). The antiviral regimen significantly reduces mortality and the number of MPX lesions (Stittelaar et al., 2006). In this regard, Tecovirimat (ST-246, TPOXX®) remains the first and only approved antiviral drug indicated for the treatment of Orthopoxvirus (Chan-Tack et al., 2019). The drug targets the F13L gene leading to impediments in the envelopment of virions and their subsequent release from the infected cells (Yang et al., 2005). The F13L protein interacts and co-localizes with BSR transmembrane glycoprotein forming the F13L-BSR complex (Husain and Moss, 2001) that is needed for viral wrapping.

However, mutations in the F13L gene have been described in a mutant clade of Cowpox virus (CPXV) that led to an 800-fold increase in the drug resistance of ST-246 which was taken to be responsible for the treatment failure (Chan-Tack et al., 2019). The drug targets the F13L gene leading to impediments in the envelopment of virions and their subsequent release from the infected cells (Yang et al., 2005). The F13L protein interacts and co-localizes with BSR transmembrane glycoprotein forming the F13L-BSR complex (Husain and Moss, 2001) that is needed for viral wrapping.

It has been demonstrated that 24 hours after exposure to lethal hMPXV in monkeys, initiation of antiviral treatment with cidofovir or with a related acyclic nucleoside phosphonate analogue is more effective than smallpox vaccination (Stittelaar et al., 2006). A case of Progressive Vaccinia (PV) treated with ST-246 and/or TPOXX® has also been described who developed ST-246 resistance during the late stages of the disease (Lederman et al., 2012). A 50-fold increase in EC50 (half maximal effective concentration) was noted within one month of isolation of the virus from the patient sample (Lederman et al., 2012). The patient was subsequently administered CMX001, an orally bioavailable prodrug of cidofovir.
Additionally, the protective efficacy of the vaccine measured by the survival of lethal hMPXV challenge is largely unaffected by concurrent TPOXX treatment, but the humoral response to the vaccine may be adversely affected. The diminished humoral responses may have contributed to increased morbidity in ACAM2000+tecvirimat-treated animals lethally challenged with hMPXV (Russo et al., 2020; Berhanu et al., 2010).

To overcome the potential development of resistance against available antivirals, Priyamvada et al., demonstrated that PAV-164, a derivative of methylene blue, is a potent inhibitor of MPX viral replication (Priyamvada et al., 2021). Resveratrol, a natural polyphenol found in grapes, berries, etc., has also been shown in vitro to significantly reduce hMPXV replication (both clades) by suppressing DNA synthesis and associated downstream gene expression (Cao et al., 2017). Another candidate antiviral is based on NIOCH-14, a derivative of tricyclodiacarboxylic acid, which causes a significant reduction in hMPXV viral production in the lungs of mice and marmots challenged with the virus (Mazurkov et al., 2016).

The recently published recommendations from the Advisory Committee on Immunization Practices (ACIP) in 2022, recommended JYNNEOS, a replication-deficient modified Vaccinia virus Ankara (MVA), as an alternative to ACAM2000 for primary vaccination (Rao et al., 2022). The vaccine does not pose risk for autoinoculation or inadvertent inoculation due to the absence of a major cutaneous reaction (“take”). The vaccine is administered in a 2-dose regimen set 28 days apart. A booster every 2 years for people with contact with more virulent orthopoxviruses and every 10 years for people with contact with low virulent orthopoxviruses has been recommended (Rao et al., 2022). Additionally, the ACIP recommended the use of JYNNEOS as a booster for those with ACAM2000 as primary vaccination. However, in a sero-study, the authors demonstrated that childhood vaccination does not provide complete protection against hMPXV, though the disease severity is reduced (Karem et al., 2007).

With the recent advances in gene-based vaccines, a DNA vaccine called 4pox has been developed and tested in different animal challenge models. The vaccine has been shown to inhibit viral shedding in vaccinated animals and prevented lethal effects of the viral infection (Golden et al., 2012; Mucker et al., 2022b). A recombinant Vaccinia virus immunoglobulin (rVIG) has been shown to possess higher neutralizing activity in vitro and in vivo when given both prophylactically as well as therapeutically (Parker et al., 2021). Another model in marmosets used a prophylactic dose of two human-chimeric monoclonal antibodies – c7D11 (against MV) and c8A (against EV) to protect against a lethal dose of MPXV (Mucker et al., 2018).

CRISPR/Cas9-based targeted antivirals delivered using adeno-associated virus (AAV) have been shown to reduce Orthopoxvirus viral titre by more than 90% in human embryonic kidney cells (Sigeist et al., 2020). Two specific genes were targeted by the authors which were found to be universally conserved across all Orthopoxvirus species – 12 L (production of mature virus, telomere binding, host-cell entry), and A17L (early viral envelope protein). A third gene E3L (affects host innate immune response) was also identified by the authors but was not tested (Sigeist et al., 2020).

Interestingly, the E3L gene has been long a front-runner candidate for any deletion mutant or subunit vaccine. However, in animal models, E3L gene deleted Vaccinia vaccine (NYCBH1E3L) failed to prevent lethal infection of MPXV, though it promoted pro-inflammatory signal transduction (Denzler et al., 2011). The lack of efficacy of such a mutant vaccine could be attributed to the need for E3L in the induction of protective T-cell epitopes (Ando et al., 2020). Whilst E3L-specific CD4+ T cells could not lyse infected cells, E3L-specific CD8+ T cells were able to lyse the infected cells if added within the first two hours of infection (due to the early expression of E3L – within 30 min of infection) (Ando et al., 2020). hMPXV contains a truncated homologue of E3 called F3L, both of which binds to the double-stranded RNA and move it away from the cellular pattern recognition receptors (PRR) (Watson et al., 1991). However, the presence of a truncated homologue confers hMPXV phenotype which is similar to wild-type Vaccinia virus, thereby pointing toward the presence of other extragenic genes that help the virus to overcome the effects of truncation (Arndt et al., 2015). Interestingly, it has been shown that in MPXV-immune adults, the virus can escape both CD4+ and CD8+ T cell-mounted antiviral response by inducing a state of unresponsiveness in the T cells (Hammarlund et al., 2008). Yet, the recovered adults can mount a potent antiviral response possibly due to either alternative antigen presentation, cross-priming, and/or the ability of some cells to evade the immunomodulatory effects of MPXV (Hammarlund et al., 2008). hMPXV has been shown to possess IFN resistance and plaque formation remained unaffected by increasing concentrations of IFN (Arndt et al., 2016), which is interesting since the IFN-α and IFN-γ levels in hMPXV+ sero-profiled patients were found to be comparable to the normal levels (Realegeno et al., 2017). Furthermore, hMPXV is known to produce less double-stranded RNA than Vaccinia virus (Arndt et al., 2016) which confers it resistance to antiviral analogues like isatin-beta-thiosemicarbazone (Arndt et al., 2016; Pennington, 1977).

With countries like the US, UK, and Canada already starting ring vaccination (vaccination of close contacts of confirmed cases), it is essential to develop safer and easier-to-distribute vaccines. To aid in the future development of vaccines against Orthopoxviruses, an online resource EPIPOX (available at: http://imed.med.ucm.es/epipox/; Accessed 12th June 2022) has been developed that allows immunoinformatic characterization of shared T-cell epitopes between Orthopoxviruses which could be used in computational reverse vaccinology (Molero-Abraham et al., 2015).

7. The puzzling mystery of 2022 outbreak

What makes the recent 2022 global outbreak interesting though is the lack of known epidemiological links to central or western Africa, indicating a possible semi-endemic equilibrium. The transmission of the virus sexually, especially amongst men who have sex with men (MSM) community poses another interesting question. Interestingly, the clade associated with the current outbreak has been identified as the WA clade which is less virulent and less transmissible amongst humans. The lack of a high degree of changes in the genetic structure of the virus (as compared with Covid-19) makes the current events interesting to observe and follow as they unfold. With climate change and increased human-animal interactions due to migration of species northwards, deforestation, petting, zoos, etc., accelerating zoonotic spillover events, it becomes even more important for public health and epidemiological institutions to detect, manage, and guide society.

8. Conclusions

Human monkeypox virus (hMPXV) has long been a neglected zoonotic pathogen with a potential for misuse as a bioweapon and/or spill-over caused pandemics. The recent outbreaks across the globe have once again highlighted the need for constant and vigilant monitoring along with the development of novel prophylactic and therapeutic modalities. The selected administration of the smallpox vaccine and waning immunity in the population can accelerate the spread of the virus. Lessons learned from the Covid-19 pandemic shall be employed in the management and containment of the human monkeypox virus.

Declarations

Ethical approval

Not applicable. All data presented in the study has been collected from open-source platforms with proper citation and/or from media sources.
Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References

Monkeypox - United Kingdom of Great Britain and Northern Ireland, 2022. World Health Organization (WHO) [online] 16th MayAvailable from. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON381. Accessed 20th May 2022.
Kraemer M., and Global health Monkeypox. Twitter post. 19th May 2022 1:36 AM. https://twitter.com/MCraemer/status/1501457471567281344.

Author contributions
NJ and EL conceptualized the present paper, whilst all authors were involved in data curation, formal analysis, and preparation of the initial draft of the manuscript. Funding acquisition was done by NJ and AR. Investigations and Methodology was led by NJ and EL. Project administration was done by NJ. Resources and software were led by NJ and AR. Supervision was done by SL and AR. Visualization was done by NJ and EL. Validation was done by SL and AR. NJ was responsible for review and editing of the final draft. All authors have read and agreed to the final version of the paper for publication.

Declaration of Competing Interest
The authors declare no conflicts of interest in regards with the present paper.

Data Availability
No data was used for the research described in the article.

Acknowledgments
The support of ECOMSIR (European Collaboration of Medical Students in Research) and Riga Stradiņš University (RSU) is greatly acknowledged.

References
Realegeno, S., Priyamvada, L., Satheshkumar, P., Alvarado, M., Ando, J., Ngo, M.C., Ando, M., Leen, A., Rooney, C.M., 2020. Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy 22 (11), 642–654. https://doi.org/10.1080/14653120.2019.1719631.

Campos-Outcalt, D., Morgan, R.L., Damon, I., Swayne, D.L., 2007. Monkeypox in the United States: 2003–2005. J. Clin. Microbiol. 45, 2069-2072. https://doi.org/10.1128/JCM.02322-06. 

Cas9 as an antiviral against Orthopoxviruses using an AAV vector. Sci. Rep. 10 (1), 1–10. https://doi.org/10.1038/s41598-020-56566-5.

Hruby, D., 2020. Co-administration of tecovirimat and ACAM2000® in murine models of orthopoxvirus disease. Virol. J. 8, 1–8. https://doi.org/10.1186/s12985-020-00149-3.

Parker, S., Delius, H., Wörl, C., Straubinger, R., Bensen, S., Ley, A., Schmidt, J., Hahn, M., Ruprecht, K.-R., 2019. Oral vaccination of cynomolgus macaques against monkeypox virus; comparison to human smallpox vaccination. PLoS ONE 14 (6), e0218796. https://doi.org/10.1371/journal.pone.0218796.

Angelo, J., Buller, R.M., Smee, D.F., Lantto, J., Nielsen, H., Jensen, A., Madsen, T., 2018. Orthopoxvirus replication by resveratrol. Front. Microbiol. 9, 1–7. https://doi.org/10.3389/fmicb.2018.00752.

Ghantous, H., Birnkrant, D., Sherwat, A.I., 2019. Assessing a drug for an eradicated infectious disease: smallpox vaccine technology protect in murine models of orthopoxvirus disease. J. Virol. 93 (21), 1–8. https://doi.org/10.1128/JVI.01151-19.

Sagripanti, J.L., Wilkins, R.B., 2001. Orthopoxviruses. In: Fields Virology (5th ed.). Lippincott Wilkins & Wilkins, Philadelphia, USA, pp. 1312–1357.

Bormotov, N.I., Skarnovich, M.A., Ovchinnikova, A.S., Titova, K.A., Galahova, D.O., Belykh, V.E., Khaydfin, S.A., Skarnovich, M.O., 2019. Monkeypox outbreaks in humans: A review of the latest epidemic in West Africa and beyond. Front. Med. 6, 1–16. https://doi.org/10.3389/fmed.2019.00049.

Faye, O., Sall, A.A., Weidmann, M., Ademowo, O.G., Hufert, F.T., Czerny, C.P., 2019. Implications for the future. Trop. Med. Infect. Dis. 1 (1), 1–8. https://doi.org/10.3390/tmids1010008.

Ghantous, H., Birnkrant, D., Sherwat, A.I., 2019. Assessing a drug for an eradicated infectious disease: smallpox vaccine technology protect in murine models of orthopoxvirus disease. J. Virol. 93 (21), 1–8. https://doi.org/10.1128/JVI.01151-19.

Rodríguez-Morales, A.J., Ortiz-Martínez, Y., Bonilla-Aldana, D.K., 2022. What has been researched about Monkeypox? A bibliometric analysis of an old zoonotic virus causing global concern. Microbes Infect. https://doi.org/10.1016/j.micinf.2022.1010993. 

Russ, A.T., Berhanu, A., Biggs, C.E., Pongsatorn, P., Pongvongse, P., 2010. Impact of ST-246 on ACAM200™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 28 (2), 1327–1335. https://doi.org/10.1016/j.vaccine.2009.05.039.

Wolfe, N.D., Rice, L.M., 2005. The emergence and rapid spread of monkeypox virus in the Democratic Republic of the Congo (COG) outbreak: implications for the future. Emerg. Infect. Dis. 11 (10), 1643–1649. https://doi.org/10.3201/eid1110.041676.

Deelder, A.M., Davidson, J., van der Kuip, D.H., van der Hoek, W., 2001. Cross-protection against monkeypox virus by vaccination with the modified vaccinia virus Ankara (MVA) vector. J. Virol. 75 (7), 3235–3241. https://doi.org/10.1128/JVI.75.7.3235-3241.2001.
Watson, J.C., Chang, H.W., Jacobs, B.L., 1991. Characterization of a vaccinia virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded RNA-dependent protein kinase. Virology 185 (1), 206–216. https://doi.org/10.1016/0042-6822(91)90768-7. Nov PMID: 1681618.

Arndt, W.D., Cotsmire, S., Trainor, K., Harrington, H., Hauns, K., Kibler, K.V., Huynh, T.P., Jacobs, B.L., 2015. Evasion of the innate immune type I interferon system by monkeypox virus. J. Virol. 89 (20), 10489–10499. https://doi.org/10.1128/JVI.00304-15. Oct Epub 2015 Aug 5. PMID: 26246580; PMCID: PMC4580173.

Hammarlund, E., Dasgupta, A., Pinilla, C., Norori, P., Früh, K., Slifka, M.K., 2008. Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. In: Proc Natl Acad Sci U S A., 105, pp. 14567–14572. https://doi.org/10.1073/pnas.0800589105. Sep 23 Epub 2008 Sep 16. PMID: 18796610; PMCID: PMC2567221.

Arndt, W.D., White, S.D., Johnson, B.P., Huynh, T., Liao, J., Harrington, H., Cotsmire, S., Kibler, K.V., Langland, J., Jacobs, B.L., 2016. Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus. Virology 497, 125–135. https://doi.org/10.1016/j.viro.2016.07.016. Oct Epub 2016 Jul 26. PMID: 27467578; PMCID: PMC5026613.

Pennington, T.H., 1977. Isatin-beta-thiosemicarbazone causes premature cessation of vaccinia virus-induced late post-replicative polypeptide synthesis. J. Gen. Virol. 35, 567–571. https://doi.org/10.1099/0022-1317-35-3-567.

Molero-Abraham, M., Glutting, J.P., Flower, D.R., Lafuente, E.M., Reche, P.A., 2015. EPIPOX: immunoinformatic characterization of the shared T-cell epitome between variola virus and related pathogenic orthopoxviruses. J. Immunol. Res. 2015, 738020 https://doi.org/10.1155/2015/738020. Epub 2015 Oct 28. PMID: 26605344; PMCID: PMC4641182.